

United States Patent and Trademark Office

HC

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

		•			
APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/088,054		04/05/2002	Willy Deleersnijder	TPP 31440	6695
	7590	10/28/2004	,	EXAMINER	
Thomas P			ULM, Jo	ULM, JOHN D	
Stevens Day 1615 L Stre		& Mosher	ART UNIT	PAPER NUMBER	
Suite 850				1646	
Washington	, DC 200	036	DATE MAILED: 10/28/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	10/088,054	DELEERSNIJDER ET AL.					
Office Action Summary	Examiner	Art Unit					
	John D. Ulm	1646					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status		,					
3) Since this application is in condition for allowar	action is non-final. nce except for formal matters, pro						
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
A) Claim(s) 1-39 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-39 are subject to restriction and/or expressions.	wn from consideration.	*					
Application Papers							
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex	epted or b) objected to by the drawing(s) be held in abeyance. Section is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).					
Priority under 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:						

Application/Control Number: 10/088,054

Art Unit: 1646

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1 to 14, 19, 21, 23, 33, 38 and 39, drawn to an isolated nucleic acid encoding an IGS3 polypeptide, the polypeptide encoded thereby and methods of use.

Group II, claims 15 and 18, only in so far as they are drawn to an antibody and method of using that antibody.

Group III, claims 16, 20, 25, 27, 29 to 32, 34, 36 and 37, only in so far as they are drawn to an agonistic compound of unspecified constitution, and method of use.

Group IV, claims 17, 22, 26, 28 29 and 35, only in so far as they are drawn to an antagonistic compound of unspecified constitution, and method of use.

Group V, claim 18, only in so far as it is drawn to a method of genetic analysis.

Group VI, claim 24, drawn to a method of producing a transgenic animal.

The inventions listed as Groups I to VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the protein of invention I, the antibody of invention II, the agonistic compound of invention III and the antagonistic compound of invention IV are chemically and structurally unrelated and, therefore, do not reflect an common inventive concept. The unifying feature of invention I is the isolated IGS3 polypeptide, which is lacking from inventions II to VI. Neither the method of genetic analysis that is invention V or the method of producing a transgenic animal that is invention VI produces or uses an isolated IGS3 polypeptide.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Application/Control Number: 10/088,054

Art Unit: 1646

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John D. Ulm whose telephone number is (571) 272-0880. The examiner can normally be reached on 9:00AM to 5:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kunz Gary can be reached on (571) 272-0887. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

JOHN ULM PRIMARY EXAMINER GROUP 1600